Achaogen (AKAO) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Needham & Company Downgrades Achaogen (AKAO) to Hold
March 16, 2016 6:52 AM EDTNeedham & Company downgraded Achaogen (NASDAQ: AKAO) from Buy to Hold.
Analyst Alan Carr commented, "Achaogen provided a 4Q15 update yesterday. Enrollment in plazomicin Phase 3 CRE trial remains slow. Mgmt has concluded that a superiority trial in this indication is not feasible and will... More
